<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297293</url>
  </required_header>
  <id_info>
    <org_study_id>B-2002/594-003</org_study_id>
    <nct_id>NCT04297293</nct_id>
  </id_info>
  <brief_title>Ramosetron OD Tablet and Postdischarge Nausea and Vomiting</brief_title>
  <official_title>Effects of Ramosetron Orally Disintegrating Tablet on the Prophylaxis of Postdischarge Nausea and Vomiting in High-risk Patients Undergoing Day Surgery Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting after general anesthesia is one of the common anesthetic&#xD;
      complications. If the patient is discharged from the hospital after surgery, proper treatment&#xD;
      may be delayed or impossible if nausea and vomiting occurred. Thus, it is necessary to&#xD;
      prevent these symptoms beforehand. Patients who underwent day-surgery will be treated with&#xD;
      prophylactic ramosetron orally disintegrating tablets to determine whether the frequency of&#xD;
      nausea and vomiting is decreased when the patient returned home after discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the occurrence of postoperative nausea</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the occurrence of postoperative vomiting</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the severity of postoperative nausea</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
    <description>Numerical rating scale range from 0 to 100 (0 = no pain, 100 = the most severe pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of patient's satisfaction score</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
    <description>Numerical rating scale range from 0 to 100 (0 = no pain, 100 = the most severe pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the number of postoperative administration of rescue antiemetic drug</measure>
    <time_frame>Postoperative 30 minute, 3 hour, 24 hour, and 48 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Day Surgery</condition>
  <arm_group>
    <arm_group_label>Ramosetron-ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)</description>
    <arm_group_label>Ramosetron-ODT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo day-surgery under general anesthesia and are discharged on the&#xD;
             day of surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Patients who are taking other serotonin receptor antagonists&#xD;
&#xD;
          -  Patients who have galactose intolerance or Lapp lactase deficiency&#xD;
&#xD;
          -  patients who have glucose-galactose malabsorption&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Jung Shin, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyun-Jung Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

